We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fewer Pathologists and More Cancer Patients Drive Pathology Market

By LabMedica International staff writers
Posted on 02 Jan 2018
The global digital pathology market was worth USD 381.8 million in 2016 and is projected to grow at a CAGR of 13.2% to reach USD 708.9 million by 2021, driven by the increased adoption of digital pathology solutions worldwide due to shortage of pathologists and rise in new cancer cases. More...
Additionally, new business models and increased FDA approvals of Whole Slide Image (WSI) scanners for primary diagnostics are expected to provide a boost to the digital pathology market.

These are the findings of Frost & Sullivan, a consulting and research firm (Santa Clara, CA, USA).

The declining number of pathologists and increase in procedural volumes due to a rise in the number of oncology cases is expected to be a key growth driver of the digital pathology market. The World Health Organization (WHO) estimates a rise of about 70% in the number of new cases over the next two decades. Digital pathology is known to enhance the productivity of pathologists by 10% to 15%, leading to an improvement in the overall efficiency of healthcare providers. Digital pathology solutions are well suited for oncology care and are useful in cancer diagnosis, as these systems allow physicians to quickly take and consider a second opinion in critical cases. Additionally, the use of digital pathology in drug discovery allows pharmaceutical companies to remove bias and provide quantifiable results.

The growing applications of digital pathology in drug development activities, increasing awareness, and FDA approval for the use of digital pathology systems in clinical applications are expected to further fuel the growth of the digital pathology market. Digital pathology devices were not approved for primary diagnosis until Philips received approval for Intellisite in April 2017, which is likely to drive higher adoption of digital pathology in primary diagnosis. Further approvals of WSIs anticipated over the next 3 to 5 years will lead to increased competition in the digital pathology market.

The share of the software segment in the digital pathology market is estimated to increase on account of an expected increase in spending on image processing and analysis software products. Moreover, increased focus on using machine learning tools and Artificial Intelligence- (AI) based algorithm for automated predictive healthcare solutions will provide a boost to the spending on software solutions.

Since machine learning and AI-based platforms enable useful clinical interpretation of whole slide images, companies are strongly focusing on developing new algorithms and updating their existing ones. Multi-spectral imaging in whole slide scanning also provides a significant growth opportunity as the capabilities to handle multiple staining using multi-spectral imaging systems allow pathologists to more accurately probe the tissue biomarkers. Hence, multi-spectral imaging in whole slide scanning holds significant growth potential due to its high adoption in the clinical segment.

In spite of the higher efficiency and clinical effectiveness of digital pathology solutions, their high cost remains one of the key restraints to market growth, especially among small-to-mid-sized laboratories. However, new business models and partnerships among vendors are expected to change this scenario in the future.

“Strategic partnerships will be essential to pushing market growth. Vendors who provide one or two components for the entire digital pathology portfolio will need to identify the right partner to devise a more robust and complete offering,” said Divyaa Ravishankar, Senior Research Analyst at Frost & Sullivan. “Additionally, vendors should also be able to provide the laboratories with a portfolio of business models.”

Related Links:
Frost & Sullivan


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.